Abstract 3951
Background
Neutrophil-lymphocyte ratio (NLR) is a predictive factor of survival in cancer, probably as a biomarker of systemic inflammation, but with limited evidence in neuroendocrine neoplasms (NENs). NENs are a very heterogeneous disease with a large range of survival from few months to many years. Stage, grade and primary tumor location are known prognostic factors, but still limited. New prognostic biomarkers are needed. The aim of this study is to evaluate the association between NRL and survival (OS) in neuroendocrine neoplasms.
Methods
Data from patients diagnosed with extra-pulmonary neuroendocrine neoplasms (Grade 1 to 3) from a Portuguese tertiary cancer center were reviewed retrospectively (January 00 - March 19). NLR was calculated at diagnosis as the ratio between neutrophils and lymphocytes.
Results
In our cohort, 116 patients were identified (52% male; median age 62yo (IQR 33-80) with neuroendocrine neoplasms: 76 gastroenteropancreatic (GEP), 32 unknown primary (UP) and 8 from other primary tumor location. 54 patients were G1/G2 and 51 patients were G3/NEC. 5year OS was different according to grade [79% (IC95% 68-91%) for G1/G2 tumors and 16% (IC95% 7-35%) for G3/NEC (p < 0.001)] and to primary tumor location [62% (95%CI 51-76%) for GEP and 15% (95%CI 6-34%) for UP (p < 0.001)]. NLR analysis started by determination of NLR median in this cohort: 2.526 (IQR 1.690-3.681). Patients were then divided in two groups: low NLR (< 2.526) and high NLR (≥2.526). 5year OS according to NLR was significantly different: 58% (IC95% 46-73%) for low NLR and 33% (ICD95% 22-49%) for high NLR (p = 0.038). After stratification by grade and primary tumor location, influence of NLR categories remains, patients with high NLR had a poor OS comparing to patients with low NLR (HR = 1.87, 95%CI 1.00-3.49, p = 0.05). A non-categorical analysis of NLR, stratified by grade and primary tumor location, showed that the risk of death increases 17% by each 1 unit rise in NLR (HR = 1.17, 95%CI 1.08-1.27, p = 0.0002).
Conclusions
Our study showed that NRL is an independent prognostic factor in survival in neuroendocrine neoplasms. Further studies are needed to evaluate the prognostic value of NLR as well as to evaluate its ability to predict response to different therapies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4390 - Phase II trial of trifluridine/tipiracil (TAS-102) in patients with advanced refractory biliary tract cancer (BTC)
Presenter: Sakti Chakrabarti
Session: Poster Display session 2
Resources:
Abstract
1025 - Liver metastases (LM) from intrahepatic cholangiocarcinoma (iCCA): Outcomes from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) registry and implications on current American Joint Committee on Cancer (AJCC) staging.
Presenter: Angela Lamarca
Session: Poster Display session 2
Resources:
Abstract
5813 - Is MGMT methylation a new therapeutic target for Biliary Tract Cancer?
Presenter: Monica Niger
Session: Poster Display session 2
Resources:
Abstract
5839 - Biliary Tract Cancers in Portuguese families with BRCA gene mutation: a retrospective study.
Presenter: Patricia Pereira
Session: Poster Display session 2
Resources:
Abstract
4338 - Selection of patients with hepatocellular carcinoma for selective internal radiation therapy based on tumour burden and liver function: a post-hoc analysis of the SARAH trial
Presenter: Daniel Palmer
Session: Poster Display session 2
Resources:
Abstract
1700 - Second-line chemotherapy (SLC) in Patients with Advanced Biliary tract and Gallbladder Cancers (ABGC) Prolongs Survival: A Retrospective Population-based Cohort Study
Presenter: Adnan Zaidi
Session: Poster Display session 2
Resources:
Abstract
5562 - Overall survival of patients with hepatocellular carcinoma receiving sorafenib versus selective internal radiation therapy with predicted dosimetry in the SARAH trial
Presenter: Neil Hawkins
Session: Poster Display session 2
Resources:
Abstract
1838 - Multicenter phase II trial of axitinib monotherapy for advanced biliary tract cancer refractory to gemcitabine-based chemotherapy
Presenter: Naohiro Okano
Session: Poster Display session 2
Resources:
Abstract
3641 - Soluble Programmed Death-ligand 1 indicate poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization
Presenter: Xiaolu Ma
Session: Poster Display session 2
Resources:
Abstract
2733 - The Prognostic Nutritional Index (PNI) is an independent predictor of survival in advanced biliary cancers (ABC) receiving first-line chemotherapy (1L).
Presenter: Francesco Caputo
Session: Poster Display session 2
Resources:
Abstract